Back

Genetic testing in patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): high diagnostic yield in patients presenting with Heart Failure 

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease (4) Cardiac Amyloidosis Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Maria Ines Vicente Soares

Centro Universitario da Unidade Local de Saude de Lisboa Ocidental, Lisboa (Portugal)

6 More presentations in this session

Presentation thumbnail
Genotype and left ventricular reverse remodelling in familial dilated cardiomyopathy with contemporary heart failure therapy - the ReaGEN study
Mr P. Mangas Palma (Porto, PT)
Abstract
Presentation thumbnail
Serum transthyretin decline: an early warning signal for heart failure in hATTR-CM
Doctor J. AGOSTINHO (Lisbon, PT)
Abstract
Presentation thumbnail
Unmasking hereditary transthyretin amyloidosis in Mexico: lessons from active field screening in a high-prevalence region. First interim analysis
Miss G. Martinez Gonzalez (MX)
Abstract
Presentation thumbnail
Shifting paradigms in amyloidosis: transition to non-invasive diagnostics and cardiovascular characterization. A 17-year real-world experience
Doctor V. Flores (Ciudad De Mexico, MX)
Abstract
Presentation thumbnail
Real world prognostic modelling and trial simulations to inform phase 3 design amid improved standard of care in ATTR-CM
Professor O. Lairez (Toulouse, FR)
Abstract

Access the full session

Session thumbnail
ePosters in myocardial disease (4)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources